Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation-Reference-Cited by-同舟云学术

Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation

Published:2020-10-26 Issue:12 Volume:13 Page:1333-1347
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Wahab Ahsan¹^ORCID,Rafae Abdul²^ORCID,Faisal Muhammad Salman³,Mushtaq Kamran⁴,Ehsan Hamid⁵,Khakwani Maria⁶,Ashraf Afia⁷,Rehan Tayyab⁸,Ahmed Zahoor⁹,Shah Zunairah¹⁰,Khan Aslam⁸,Anwer Faiz¹¹^ORCID

Affiliation:

1. Internal Medicine/Hospital Medicine Department, University of Alabama at Birmingham, Montgomery, AL, USA

2. Internal Medicine Residency Program, McLaren Regional Medical Center, Flint, MI, USA

3. Internal Medicine Residency Program, Allegheny Health Network, Pittsburgh, PA, USA

4. Internal Medicine/Hospital Medicine Department, Northeast Internal Medicine Associates, LaGrange, IN, USA

5. Biomedical Sciences/Biohazardous Threat Agents & Emerging Infectious Diseases Department, Georgetown University, Washington, DC, USA

6. Internal Medicine Department, Anne Arundel Medical Center, Annapolis, MD, USA

7. Internal Medicine Department, Lahore Medical and Dental College, Lahore, Pakistan

8. Internal Medicine Department, Allama Iqbal Medical College, Lahore, Pakistan

9. Internal Medicine Department, King Edward Medical University, Lahore, Pakistan

10. Internal Medicine Residency Program, Louis A. Weis Memorial Hospital, Chicago, IL, USA

11. Hematology Oncology Department, Stem Cell Transplantation Multiple Myeloma Program, Cleveland Clinic, Cleveland, Ohio, USA

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1839886

Reference52 articles.

1. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

2. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

4. Have drug combinations supplanted stem cell transplantation in myeloma?

5. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on the Treatment of Multiple Myeloma;The Oncologist;2023-11-23

2. Current status of drug repositioning in hematology;Expert Review of Hematology;2021-11-02